Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patients

Comparison of drug efficacy between linaclotide and lubiprostone in constipation-predominant irritable bowel syndrome patients - A clinical trial about laxative products for constipation-predominant irritable bowel syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028709

Enrollment

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

constipation-predominant irritable bowel syndrome

Interventions

taking lubiprostone once per day for two weeks taking linaclotide once ot two times per day for two weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients diagnosed as constipation-predominant irritable bowel syndrome according to ROME 4 and who don't take lubiprostone either linaclotide

Exclusion criteria

Exclusion criteria: systemic inflammatory disease, malignancy disease, history of abdominal surgery

Design outcomes

Primary

Measure	Time frame
Reduction of GSRS scores and SF-8 scores two weeks after starting medication	—

Secondary

Measure	Time frame
Association of drug efficacy with gene polymorphisms and serum cytokines	—

Countries

Japan

Contacts

Public ContactAkiko Shiotani

Kawasaki Medical School Gastroenterology

shiotani@med.kawasaki-m.ac.jp086-462-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026